## Thomas N Kakuda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/888728/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clinical Therapeutics, 2000, 22, 685-708.	2.5	545
2	Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. Aids, 2002, 16, 551-560.	2.2	133
3	The Cellular Pharmacology of Nucleoside―and Nucleotideâ€Analogue Reverseâ€Transcriptase Inhibitors and Its Relationship to Clinical Toxicities. Clinical Infectious Diseases, 2004, 38, 743-753.	5.8	127
4	Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?. Current Opinion in Infectious Diseases, 2000, 13, 5-11.	3.1	121
5	Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. Aids, 2003, 17, 2159-2168.	2.2	121
6	Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. Aids, 1999, 13, 2311.	2.2	120
7	Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. Gastroenterology, 2019, 156, 1392-1403.e7.	1.3	115
8	Zidovudine triphosphate and lamivudine triphosphate concentration–response relationships in HIV-infected persons. Aids, 2000, 14, 2137-2144.	2.2	103
9	Clinical Pharmacokinetics and Pharmacodynamics of Etravirine. Clinical Pharmacokinetics, 2009, 48, 561-574.	3.5	101
10	Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2008, 52, 4228-4232.	3.2	94
11	Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers. Antiviral Therapy, 2007, 12, 789-796.	1.0	91
12	Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs. Clinical Pharmacokinetics, 2011, 50, 25-39.	3.5	70
13	Mitochondrial toxic effects and ribavirin. Lancet, The, 2001, 357, 1802-1803.	13.7	66
14	Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir. Antimicrobial Agents and Chemotherapy, 2001, 45, 236-242.	3.2	62
15	Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Research and Therapy, 2014, 11, 39.	1.7	58
16	A pharmacokinetic study of etravirine (TMC125) coâ€administered with ranitidine and omeprazole in HIV–negative volunteers. British Journal of Clinical Pharmacology, 2008, 66, 508-516.	2.4	50
17	Total and unbound darunavir pharmacokinetics in pregnant women infected with <scp>HIV</scp> â€1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Medicine, 2014, 15, 50-56.	2.2	49
18	Pharmacokinetics of darunavir in fixedâ€dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. Journal of Clinical Pharmacology, 2014, 54, 949-957.	2.0	44

THOMAS N KAKUDA

#	Article	IF	CITATIONS
19	Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine. Pharmacotherapy, 2008, 28, 1215-1222.	2.6	39
20	Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antiviral Therapy, 2010, 15, 711-720.	1.0	37
21	Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers. Antiviral Therapy, 2014, 19, 597-606.	1.0	36
22	Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIVâ€Negative Volunteers. Journal of Clinical Pharmacology, 2008, 48, 322-329.	2.0	35
23	Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. Contraception, 2009, 80, 44-52.	1.5	35
24	Drug Interactions between HIV Protease Inhibitors and Acid-Reducing Agents. Clinical Pharmacokinetics, 2008, 47, 75-89.	3.5	33
25	Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials. Antimicrobial Agents and Chemotherapy, 2011, 55, 2290-2296.	3.2	32
26	Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antiviral Therapy, 2008, 13, 655-661.	1.0	32
27	Assessment of the steadyâ€state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Medicine, 2009, 10, 173-181.	2.2	29
28	Pharmacokinetics of Elvitegravir and Etravirine following Coadministration of Ritonavir-Boosted Elvitegravir and Etravirine. Antiviral Therapy, 2008, 13, 1011-1017.	1.0	29
29	Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir. Journal of Antimicrobial Chemotherapy, 2014, 69, 2591-2605.	3.0	27
30	Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir. AAPS Journal, 2019, 21, 1.	4.4	27
31	Clinical perspective on antiretroviral drug–drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antiviral Therapy, 2010, 15, 817-829.	1.0	26
32	Etravirine Has No Effect on QT and Corrected QT Interval in HIV-Negative Volunteers. Annals of Pharmacotherapy, 2008, 42, 757-765.	1.9	25
33	Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Research and Treatment, 2012, 2012, 1-10.	0.7	25
34	Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antiviral Therapy, 2007, 12, 789-96.	1.0	25
35	Efficacy and Safety of Darunavir/Ritonavir at 48 Weeks in Treatment-naÃ⁻ve, HIV-1–infected Adolescents. Pediatric Infectious Disease Journal, 2014, 33, 940-945.	2.0	23
36	Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a twoâ€panel, twoâ€way, twoâ€period, randomized trial. HIV Medicine, 2013, 14, 421-429.	2.2	21

THOMAS N KAKUDA

#	Article	IF	CITATIONS
37	Pharmacokinetics of onceâ€daily darunavir/ritonavir in <scp>HIV</scp> â€1–infected pregnant women. HIV Medicine, 2016, 17, 643-652.	2.2	20
38	Effect of Food and Ranitidine on Saquinavir Pharmacokinetics and Gastric pH in Healthy Volunteers. Pharmacotherapy, 2006, 26, 1060-1068.	2.6	17
39	The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects. Journal of Clinical Pharmacology, 2014, 54, 422-431.	2.0	17
40	Etravirine in treatmentâ€experienced, <scp>HIV</scp> â€lâ€infected children and adolescents: 48â€week safety, efficacy and resistance analysis of the phase <scp>II PIANO</scp> study. HIV Medicine, 2014, 15, 513-524.	2.2	17
41	Pharmacokinetics of Saquinavir With Atazanavir or Low-Dose Ritonavir Administered Once Daily (ASPIRE I) or Twice Daily (ASPIRE II) in Seronegative Volunteers. Journal of Clinical Pharmacology, 2007, 47, 201-208.	2.0	15
42	Safety and Efficacy of Darunavir/Ritonavir in Treatment-experienced Pediatric Patients. Pediatric Infectious Disease Journal, 2015, 34, e132-e137.	2.0	14
43	Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents. Aids, 2012, 26, 447-455.	2.2	13
44	Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial. Journal of Clinical Pharmacology, 2014, 54, 563-573.	2.0	13
45	Single―and multipleâ€dose pharmacokinetics and safety of pimodivir, a novel, nonâ€nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 openâ€label study in healthy volunteers. British Journal of Clinical Pharmacology, 2018 84 2663-2672	2.4	13
46	Drug Interactions with New and Investigational Antiretrovirals. Clinical Pharmacokinetics, 2010, 49, 67-68.	3.5	12
47	Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. Journal of Antimicrobial Chemotherapy, 2014, 69, 728-734.	3.0	12
48	The <scp>I</scp> ntelence <scp>aNd pRezist</scp> a <scp>O</scp> nce <scp>A D</scp> ay <scp>S</scp> tudy ( <scp>INROADS</scp> ): a multicentre, singleâ€arm, openâ€label study of etravirine and darunavir/ritonavir as dual therapy in <scp>HIV</scp> â€lâ€infected early treatmentâ€experienced subjects. HIV Medicine, 2015, 16, 288-296.	2.2	12
49	Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antiviral Therapy, 2008, 13, 655-61.	1.0	12
50	Darunavir/cobicistat once daily for the treatment of HIV. Expert Review of Anti-Infective Therapy, 2015, 13, 691-704.	4.4	11
51	Steadyâ€6tate Pharmacokinetics of Etravirine and Lopinavir/Ritonavir Melt Extrusion Formulation, Alone and in Combination, in Healthy HIVâ€Negative Volunteers. Journal of Clinical Pharmacology, 2013, 53, 202-210.	2.0	10
52	Pharmacokinetics of darunavir after administration of an oral suspension with lowâ€dose ritonavir and with or without food. Clinical Pharmacology in Drug Development, 2014, 3, 346-352.	1.6	9
53	Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged <b>≥</b> 3 to <12 Years. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 406-414.	2.5	9
54	Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antiviral Therapy, 2008, 13, 1011-7.	1.0	9

THOMAS N KAKUDA

#	Article	IF	CITATIONS
55	<b>Etravirine: Clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance</b> . Antiviral Therapy, 2010, 15, 803-816.	1.0	8
56	Pharmacokinetics and Shortâ€Term Safety of Etravirine in Combination With Fluconazole or Voriconazole in HIVâ€Negative Volunteers. Journal of Clinical Pharmacology, 2013, 53, 41-50.	2.0	8
57	Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 805-816.	0.6	8
58	Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine. Clinical Pharmacokinetics, 2017, 56, 525-536.	3.5	8
59	Shortâ€Duration ALâ€335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis. Hepatology, 2018, 68, 2145-2157.	7.3	8
60	Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies. International Journal of Clinical Pharmacology and Therapeutics, 2013, 51, 725-736.	0.6	8
61	Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-NaÃ <sup>-</sup> ve Patients. HIV Clinical Trials, 2013, 14, 92-98.	2.0	7
62	JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B. Antiviral Therapy, 2022, 27, 135965352210938.	1.0	7
63	Comment on: Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. Journal of Antimicrobial Chemotherapy, 2006, 58, 220-221.	3.0	6
64	Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients. AIDS Research and Treatment, 2015, 2015, 1-11.	0.7	6
65	Pharmacokinetics, safety, and tolerability of the 2―and 3â€directâ€acting antiviral combination of <scp>AL</scp> â€335, odalasvir, and simeprevir in healthy subjects. Pharmacology Research and Perspectives, 2018, 6, e00395.	2.4	5
66	Reply to Stevens et al. Clinical Infectious Diseases, 2004, 39, 878-879.	5.8	4
67	Etravirine in the Treatment of HIV-1: A Clinical Overview for Healthcare Professionals. Current HIV Research, 2010, 8, 564-576.	0.5	4
68	Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIVâ€1â€Infected, Treatmentâ€Experienced Children and Adolescents in PIANO. Journal of Clinical Pharmacology, 2016, 56, 1395-1405.	2.0	4
69	Optimizing dosing strategies for the combination of atazanavir plus saquinavir. Aids, 2004, 18, 704-705.	2.2	3
70	Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers. Antiviral Therapy, 2021, 26, 13-24.	1.0	2
71	Design of antiretroviral drug interaction studies. Current Opinion in HIV and AIDS, 2008, 3, 313-318.	3.8	1

72 Antiretroviral drug interactions. , 2005, , 305-318.

#	Article	IF	CITATIONS
73	Antiretroviral drug interactions. , 0, , 360-381.		0
74	Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach. AAPS Journal, 2018, 20, 111.	4.4	0